Akero Therapeutics, Inc.

NasdaqGS:AKRO Stock Report

Market Cap: US$4.5b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Akero Therapeutics Past Earnings Performance

Past criteria checks 0/6

Akero Therapeutics's earnings have been declining at an average annual rate of -28.9%, while the Biotechs industry saw earnings growing at 23.9% annually.

Key information

-28.91%

Earnings growth rate

-8.35%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth raten/a
Return on equity-30.58%
Net Marginn/a
Last Earnings Update30 Sep 2025

Recent past performance updates

No updates

Recent updates

Seeking Alpha • Oct 10

Akero: Novartis Acquisition Puts Focus On Unprecedented MASH Data With EFX

Summary Akero Therapeutics is being acquired by Novo Nordisk for up to $5.2 billion, driven by strong phase 2b results for EFX in F2/F3 pre-cirrhotic and compensated cirrhosis F4 MASH patients. Akero's EFX showed unprecedented reversal of cirrhosis and significant fibrosis improvement in the HARMONY and SYMMETRY studies, respectively, positioning it as a leader in FGF21 analogs. The acquisition includes $54 per share upfront as cash and a $6 per share CVR contingent on FDA approval for compensated cirrhosis due to MASH patients by 2031. I maintain a 'Strong Buy' rating on AKRO, citing ongoing phase 3 SYNCHRONY progress and the transformative potential of the Novo Nordisk deal set forth. Read the full article on Seeking Alpha
Seeking Alpha • Apr 06

Akero Therapeutics: Cirrhosis Reversal Data Derisks The Stock

Summary Akero Therapeutics' EFX showed remarkable efficacy in reversing cirrhosis in the long-term SYMMETRY trial, a significant milestone in MASH treatment. EFX demonstrated consistent efficacy across different MASH stages, positioning it uniquely against competitors like Resmetirom, which only targets F2 and F3 MASH. Akero's financial health is strong, with a cash runway until 2028, bolstered by a recent $350 million upsized offering. Despite promising data, potential delays and reliance on surrogate endpoints pose risks; a cautious approach with a pilot position and accumulation at dips is advised. Read the full article on Seeking Alpha
Seeking Alpha • Jan 28

Some Good MASH/NASH News From Akero Therapeutics

Summary One of the best candidates for treatment of MASH recently has been a hormone called FGF21. There are three different FGF21 receptor types, and there have been several analogs of the hormone (with different pharmacokinetic and receptor-binding profiles) entering clinical trials. One of these (exfruxifermin) just produced some extremely interesting clinical results. Akero Therapeutics reported 96-week data in its trial of advanced MASH patients, and there seem really significant signs of improvement compared to placebo. We can expect a number of other trial results from both AKRO and their competitors in the coming months. Read the full article on Seeking Alpha
Seeking Alpha • Dec 31

Akero Therapeutics: Where This Potential MASH Play Stands Currently

Summary Akero Therapeutics, Inc. is a clinical-stage biotech firm that is developing therapies to restore metabolic balance and improve health, with a market cap near $2 billion. The company has made some pipeline progress since we last visited this potential MASH play back in August of last year. Akero's primary and only candidate is moving into Phase 3 development, and the stock has some enthusiastic views on it within the analyst firm community. An updated analysis around AKRO stock follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Sep 20

Akero Therapeutics: Good Candidate For The MASH Basket

Summary Akero Therapeutics' Efruxifermin (EFX) showed strong results in pre-cirrhotic MASH, but failed in cirrhotic MASH, impacting stock performance. The MASH market is highly competitive with many pipeline drugs and one approved drug, resmetirom, creating significant risk for AKRO. Akero has a solid cash runway until 2027, providing financial stability for ongoing trials and potential future data releases. EFX's potential success in early-stage MASH makes AKRO a viable part of a diversified investment in MASH players like MDGL, ETNB, VKTX, IVA and IONS. Read the full article on Seeking Alpha
Seeking Alpha • Apr 03

Akero Therapeutics' EFX Data Warrants Caution

Summary Akero Therapeutics' week 96 Harmony trial data findings and reporting warrant caution due to biomarker data regression and inconsistent findings. In our view, Efruxifermin's phase 2 data reveal a fragile efficacy profile and a concerning safety record, casting doubt on its potential to successfully translate into phase 3 trials. MASH space growing competition and future sales of Resmetirom will significantly impact valuations. Read the full article on Seeking Alpha
Seeking Alpha • Mar 04

Akero: Phase 2b NASH Data Bodes Well For Phase 3 SYNCHRONY Program

Summary Akero Therapeutics, Inc. preliminary positive 96-week results from the phase 2b HARMONY study achieved, which used EFX for the treatment of pre-cirrhotic MASH patients with F2-F3 Fibrosis. The global non-alcoholic steatohepatitis market size is expected to reach $14.53 billion by 2028. 96-week results from the phase 2b SYMMETRY study, using EFX for the treatment of patients with compensated cirrhosis (F4) MASH, expected in Q1 of 2024. Akero Therapeutics has $569.3 million in cash as of December 31, 2023; Enough cash to fund its operations into 2026. Read the full article on Seeking Alpha

Revenue & Expenses Breakdown

How Akero Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:AKRO Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 250-29343287
30 Jun 250-28441280
31 Mar 250-26940266
31 Dec 240-25238247
30 Sep 240-23738232
30 Jun 240-20436198
31 Mar 240-17933171
31 Dec 230-15231142
30 Sep 230-12030107
30 Jun 230-1163393
31 Mar 230-1123187
31 Dec 220-1123085
30 Sep 220-1212895
30 Jun 220-1102189
31 Mar 220-1122092
31 Dec 210-1011982
30 Sep 210-981880
30 Jun 210-951878
31 Mar 210-821667
31 Dec 200-791565
30 Sep 200-651452
30 Jun 200-591349
31 Mar 200-501142
31 Dec 190-44937
30 Sep 190-90726
30 Jun 190-86513
31 Mar 190-87316
31 Dec 180-82212
30 Sep 180-22111

Quality Earnings: AKRO is currently unprofitable.

Growing Profit Margin: AKRO is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: AKRO is unprofitable, and losses have increased over the past 5 years at a rate of 28.9% per year.

Accelerating Growth: Unable to compare AKRO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AKRO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (52%).

Return on Equity

High ROE: AKRO has a negative Return on Equity (-30.58%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/08 01:19
End of Day Share Price 2025/12/08 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Akero Therapeutics, Inc. is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason ZemanskyBofA Global Research
Alexandria HammondBofA Global Research
Citi ResearchCitigroup Inc